Literature DB >> 33608538

Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity.

Matthias Becker1, Monika Strengert2,3, Ulrich Rothbauer1,4, Daniel Junker1, Philipp D Kaiser1, Tobias Kerrinnes5, Bjoern Traenkle1,4, Heiko Dinter1,4, Julia Häring1, Stéphane Ghozzi2, Anne Zeck1, Frank Weise1, Andreas Peter6,7,8, Sebastian Hörber6,7,8, Simon Fink1, Felix Ruoff1, Alex Dulovic1, Tamam Bakchoul9, Armin Baillot10, Stefan Lohse11, Markus Cornberg12, Thomas Illig13, Jens Gottlieb14,15, Sigrun Smola11, André Karch16, Klaus Berger16, Hans-Georg Rammensee17,18,19, Katja Schenke-Layland1,19,20,21, Annika Nelde17,19,22, Melanie Märklin19,21, Jonas S Heitmann19,21, Juliane S Walz17,19,22,23, Markus Templin1, Thomas O Joos1, Gérard Krause2,3, Nicole Schneiderhan-Marra24.   

Abstract

The humoral immune response to SARS-CoV-2 is a benchmark for immunity and detailed analysis is required to understand the manifestation and progression of COVID-19, monitor seroconversion within the general population, and support vaccine development. The majority of currently available commercial serological assays only quantify the SARS-CoV-2 antibody response against individual antigens, limiting our understanding of the immune response. To overcome this, we have developed a multiplex immunoassay (MultiCoV-Ab) including spike and nucleocapsid proteins of SARS-CoV-2 and the endemic human coronaviruses. Compared to three broadly used commercial in vitro diagnostic tests, our MultiCoV-Ab achieves a higher sensitivity and specificity when analyzing a well-characterized sample set of SARS-CoV-2 infected and uninfected individuals. We find a high response against endemic coronaviruses in our sample set, but no consistent cross-reactive IgG response patterns against SARS-CoV-2. Here we show a robust, high-content-enabled, antigen-saving multiplex assay suited to both monitoring vaccination studies and facilitating epidemiologic screenings for humoral immunity towards pandemic and endemic coronaviruses.

Entities:  

Year:  2021        PMID： 33608538     DOI： 10.1038/s41467-021-20973-3

Source DB:  PubMed          Journal:  Nat Commun        ISSN： 2041-1723            Impact factor:   14.919


  1 in total

Review 1.  Is innate immunity our best weapon for flattening the curve?

Authors:  Leonard Angka; Marisa Market; Michele Ardolino; Rebecca C Auer
Journal:  J Clin Invest       Date:  2020-08-03       Impact factor: 14.808
  1 in total
  21 in total

1.  On the caveats of a multiplex test for SARS-CoV-2 to detect seroconversion after infection or vaccination.

Authors:  Lorena O Fernandes-Siqueira; Fabiana A P Ferreira; Bruna G Sousa; Nathane C Mebus-Antunes; Thais C Neves-Martins; Fabio C L Almeida; Gustavo C Ferreira; Didier Salmon; Luciana S Wermelinger; Andrea T Da Poian
Journal:  Sci Rep       Date:  2022-06-20       Impact factor: 4.996

Review 2.  Advances and Utility of the Human Plasma Proteome.

Authors:  Eric W Deutsch; Gilbert S Omenn; Zhi Sun; Michal Maes; Maria Pernemalm; Krishnan K Palaniappan; Natasha Letunica; Yves Vandenbrouck; Virginie Brun; Sheng-Ce Tao; Xiaobo Yu; Philipp E Geyer; Vera Ignjatovic; Robert L Moritz; Jochen M Schwenk
Journal:  J Proteome Res       Date:  2021-10-21       Impact factor: 5.370

3.  Persisting Salivary IgG Against SARS-CoV-2 at 9 Months After Mild COVID-19: A Complementary Approach to Population Surveys.

Authors:  Hassan Alkharaan; Shaghayegh Bayati; Cecilia Hellström; Soo Aleman; Annika Olsson; Karin Lindahl; Gordana Bogdanovic; Katie Healy; Georgios Tsilingaridis; Patricia De Palma; Sophia Hober; Anna Månberg; Peter Nilsson; Elisa Pin; Margaret Sällberg Chen
Journal:  J Infect Dis       Date:  2021-08-02       Impact factor: 7.759

4.  Robust and durable serological response following pediatric SARS-CoV-2 infection.

Authors:  Hanna Renk; Alex Dulovic; Alina Seidel; Matthias Becker; Dorit Fabricius; Maria Zernickel; Daniel Junker; Rüdiger Groß; Janis Müller; Alexander Hilger; Sebastian F N Bode; Linus Fritsch; Pauline Frieh; Anneke Haddad; Tessa Görne; Jonathan Remppis; Tina Ganzemueller; Andrea Dietz; Daniela Huzly; Hartmut Hengel; Klaus Kaier; Susanne Weber; Eva-Maria Jacobsen; Philipp D Kaiser; Bjoern Traenkle; Ulrich Rothbauer; Maximilian Stich; Burkhard Tönshoff; Georg F Hoffmann; Barbara Müller; Carolin Ludwig; Bernd Jahrsdörfer; Hubert Schrezenmeier; Andreas Peter; Sebastian Hörber; Thomas Iftner; Jan Münch; Thomas Stamminger; Hans-Jürgen Groß; Martin Wolkewitz; Corinna Engel; Weimin Liu; Marta Rizzi; Beatrice H Hahn; Philipp Henneke; Axel R Franz; Klaus-Michael Debatin; Nicole Schneiderhan-Marra; Ales Janda; Roland Elling
Journal:  Nat Commun       Date:  2022-01-10       Impact factor: 14.919

5.  Comirnaty-Elicited and Convalescent Sera Recognize Different Spike Epitopes.

Authors:  Sascha Hein; Nuka Ivalu Benz; Jonathan Eisert; Marie-Luise Herrlein; Doris Oberle; Michael Dreher; Julia C Stingl; Christoph Hildt; Eberhard Hildt
Journal:  Vaccines (Basel)       Date:  2021-12-01

Review 6.  Passive Immunity Should and Will Work for COVID-19 for Some Patients.

Authors:  Nevio Cimolai
Journal:  Clin Hematol Int       Date:  2021-04-16

7.  Evidence for increased SARS-CoV-2 susceptibility and COVID-19 severity related to pre-existing immunity to seasonal coronaviruses.

Authors:  Paul R Wratil; Niklas A Schmacke; Burak Karakoc; Alex Dulovic; Daniel Junker; Matthias Becker; Ulrich Rothbauer; Andreas Osterman; Patricia M Spaeth; Adrian Ruhle; Madeleine Gapp; Stephanie Schneider; Maximilian Muenchhoff; Johannes C Hellmuth; Clemens Scherer; Julia Mayerle; Martin Reincke; Juergen Behr; Stefan Kääb; Bernhard Zwissler; Michael von Bergwelt-Baildon; Josef Eberle; Lars Kaderali; Nicole Schneiderhan-Marra; Veit Hornung; Oliver T Keppler
Journal:  Cell Rep       Date:  2021-12-07       Impact factor: 9.423

8.  Response to Vaccination Against SARS-CoV-2 in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis With Renal Involvement.

Authors:  Jack E Carruthers; James Wells; Arun Gupta; Delordson Kallon; Amber Cox; Neuza Pina; Muhammad Magdi Yaqoob; Ravindra Rajakariar
Journal:  Front Med (Lausanne)       Date:  2022-01-20

9.  Persistence of Anti-SARS-CoV-2 Antibodies in Long Term Care Residents Over Seven Months After Two COVID-19 Outbreaks.

Authors:  Guadalein Tanunliong; Aaron Liu; Rohit Vijh; Tamara Pidduck; Jesse Kustra; Ana Citlali Márquez; Alexandra Choi; Meghan McLennan; Althea Hayden; Christy Kearney; Soren Gantt; Mel Krajden; Muhammad Morshed; Agatha N Jassem; Inna Sekirov
Journal:  Front Immunol       Date:  2022-01-03       Impact factor: 7.561

10.  Single-Domain Antibodies for Targeting, Detection, and In Vivo Imaging of Human CD4+ Cells.

Authors:  Bjoern Traenkle; Philipp D Kaiser; Stefania Pezzana; Jennifer Richardson; Marius Gramlich; Teresa R Wagner; Dominik Seyfried; Melissa Weldle; Stefanie Holz; Yana Parfyonova; Stefan Nueske; Armin M Scholz; Anne Zeck; Meike Jakobi; Nicole Schneiderhan-Marra; Martin Schaller; Andreas Maurer; Cécile Gouttefangeas; Manfred Kneilling; Bernd J Pichler; Dominik Sonanini; Ulrich Rothbauer
Journal:  Front Immunol       Date:  2021-12-09       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.